相关实验视频
Updated: May 22, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.5K
药剂师整合以支持持续葡萄糖监测启动:一种以合作为中心,以患者为中心的方法
James Thurston1, Hanlin Li1, Mangala Rajan2
1Department of Pharmacy, New York-Presbyterian Hospital, New York, NY, USA.
Journal of pharmacy practice
|March 14, 2025
概括
临床药剂师通过协助持续血糖监测 (CGM) 的启动,显著改善了糖尿病患者的血糖控制. 药剂师的支持,特别是在协作药物治疗管理下,导致A1c大幅减少.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 糖尿病管理 糖尿病管理
背景情况:
- 持续的葡萄糖监测 (CGM) 改善了糖尿病的血糖控制.
- 临床药剂师可以通过教育和支持来加强CGM的采用.
- 关于药剂师辅助CGM启动的有效性存在有限的证据.
研究的目的:
- 评估临床药剂师辅助的CGM实施对血糖控制的影响.
- 评估药剂师支持的CGM启动后A1c水平的变化.
主要方法:
- 追溯的前后研究设计.
- 对接受药剂师协助进行CGM启动的患者A1c变化的分析 (2019年1月至2023年12月).
- 在协作药物治疗管理 (CDTM) 和非协作药物治疗管理 (CDTM) 患者之间的A1c变化比较.
主要成果:
- 药剂师辅助的CGM启动导致A1c平均值显著下降 -0.71 (P < 0.001).
- 在CDTM小组中,A1c平均降低幅度更大,为-1.60 (P = 0.002).
- 非CDTM小组实现了平均A1c降低-0.50 (P < 0.001).
结论:
- 临床药剂师通过CGM支持有效降低糖尿病患者的A1c水平.
- 药剂师领导的CGM启动,教育和跟进是有益的.
- 药剂师根据CDTM协议管理的患者经历了最显著的A1c改善.
相关概念视频
SBAR II: Application of SBAR
4.3K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
4.3K
Pulse rhythm
749
Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
749
Diabetes: Management and Pharmacotherapy
220
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
220
Hypoglycemia and Glucagon
146
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
146
Oral Hypoglycemic Agents: Glinides
124
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
124
Glucagon-like Receptor Agonists
281
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
281

